Evoke Pharma (EVOK)
(Delayed Data from NSDQ)
$0.50 USD
+0.02 (3.96%)
Updated Jul 26, 2024 03:55 PM ET
After-Market: $0.50 0.00 (-0.22%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
Evoke Pharma, Inc. [EVOK]
Reports for Purchase
Showing records 41 - 60 ( 79 total )
Company: Evoke Pharma, Inc.
Industry: Medical - Generic Drugs
FDA Feedback Provides a Glimmer of Hope for Gimoti; Raising Price Target
Provider: Rodman & Renshaw, Co.
Company: Evoke Pharma, Inc.
Industry: Medical - Generic Drugs
FDA Feedback Provides a Glimmer of Hope for Gimoti; Raising Price Target
Provider: H.C. Wainwright & Co., Inc.
Company: Evoke Pharma, Inc.
Industry: Medical - Generic Drugs
3Q16 Results Reported; Gimoti? Path Uncertain; Reiterate Neutral and Lowering Price Target
Provider: Rodman & Renshaw, Co.
Company: Evoke Pharma, Inc.
Industry: Medical - Generic Drugs
Evoke Pharma continues to pursue FDA approval of Gimoti despite failed trial
Provider: Feltl & Company
Analyst: HAYNOR B
Company: Evoke Pharma, Inc.
Industry: Medical - Generic Drugs
3Q16 Results Reported; Gimoti - Path Uncertain; Reiterate Neutral and Lowering Price Target
Provider: H.C. Wainwright & Co., Inc.
Company: Evoke Pharma, Inc.
Industry: Medical - Generic Drugs
Company: Evoke Pharma, Inc.
Industry: Medical - Generic Drugs
2Q16 Results Reported; Firmer Financial Footing; Raising Price Target to $2.50 Per Share
Provider: Rodman & Renshaw, Co.
Company: Evoke Pharma, Inc.
Industry: Medical - Generic Drugs
2Q16 Results Reported; Firmer Financial Footing; Raising Price Target to $2.50 Per Share
Provider: H.C. Wainwright & Co., Inc.
Company: Evoke Pharma, Inc.
Industry: Medical - Generic Drugs
EVK-001 Phase 3 Trial Misses Primary Endpoint; Downgrading to Neutral with $2 Price Target
Provider: Rodman & Renshaw, Co.
Company: Evoke Pharma, Inc.
Industry: Medical - Generic Drugs
EVK-001 Phase 3 Trial Misses Primary Endpoint; Downgrading to Neutral with $2 Price Target
Provider: H.C. Wainwright & Co., Inc.
Company: Evoke Pharma, Inc.
Industry: Medical - Generic Drugs
Phase 3 results of EVK-001 miss primary endpoint, lower target to $0.20
Provider: Feltl & Company
Analyst: HAYNOR B
Company: Evoke Pharma, Inc.
Industry: Medical - Generic Drugs
Phase 3 Data Release Imminent; Reiterate Buy
Provider: Rodman & Renshaw, Co.
Company: Evoke Pharma, Inc.
Industry: Medical - Generic Drugs
Phase 3 Data Release Imminent; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Company: Evoke Pharma, Inc.
Industry: Medical - Generic Drugs
2016 Digestive Disease Week Recap
Provider: Rodman & Renshaw, Co.
Company: Evoke Pharma, Inc.
Industry: Medical - Generic Drugs
2016 Digestive Disease Week Recap
Provider: H.C. Wainwright & Co., Inc.
Company: Evoke Pharma, Inc.
Industry: Medical - Generic Drugs
Q1 EPS slightly worse than estimated, top-line data on horizon, reiterate STRONG BUY
Provider: Feltl & Company
Analyst: HAYNOR B
Company: Evoke Pharma, Inc.
Industry: Medical - Generic Drugs
1Q 2016 Financial Results Reported: Phase 3 Data Fast Approaching; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Company: Evoke Pharma, Inc.
Industry: Medical - Generic Drugs
1Q 2016 Financial Results Reported: Phase 3 Data Fast Approaching; Reiterate Buy
Provider: Rodman & Renshaw, Co.
Company: Evoke Pharma, Inc.
Industry: Medical - Generic Drugs
Company: Evoke Pharma, Inc.
Industry: Medical - Generic Drugs
Phase 3 Enrollment Complete, Top-Line Data Release Next; Reiterate Buy
Provider: Rodman & Renshaw, Co.